Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Diabetes Mellitus, Type 2
and you are
between 18 and 65
years old
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The purpose of this study is to determine the effect of GLP-1 receptor agonist on inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese

Provided treatments

  • Drug: Exenatide
  • Drug: BIAsp30
  • Drug: Metformin
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03018665. The sponsor of the trial is First Hospital of Jilin University and it is looking for 200 volunteers for the current phase.
Official trial title:
A Randomized,Active-controlled,Open-label Clinical Trial to Evaluate the Effect of GLP-1 Receptor Agonist (Exenatide Injection) in Combination With Metformin Therapy Compared to Premixed Insulin (BIAsp30) in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese